INmune Bio (INMB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
The meeting was called to order virtually to increase inclusivity and reach more stockholders.
The agenda and order of business were outlined, with business matters addressed first and Q&A scheduled for the end.
Board and executive committee updates
Nominees for board election included David Moss, Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen.
Shareholder proposals
Three proposals were presented: election of directors, ratification of the independent auditor, and approval of the amended 2021 Stock Incentive Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from INmune Bio
- Regulatory and clinical progress drove a sharply reduced net loss, but liquidity risks persist.INMB
Q2 2026 - CORDStrom and XPro1595 advance to pivotal stages, targeting systemic RDEB and Alzheimer's.INMBCorporate presentation
- Net loss narrowed, cash reserves strong, but liquidity concerns persist amid regulatory progress.INMBQ1 2026
- Virtual meeting to elect directors, ratify auditor, and expand equity plan with evergreen provision.INMBProxy filing
- Late-stage clinical progress and regulatory filings drive 2026 outlook; cash runway through Q1 2027.INMBQ4 2025
- Late-stage therapies for RDEB and Alzheimer's advance toward 2026 filings, showing strong efficacy.INMBCorporate presentation
- CORDStrom reduced itch and pain, improved healing, and showed strong safety in RDEB children.INMBStudy update
- XPro demonstrated safety and cognitive benefit in biomarker-defined early Alzheimer's patients.INMBStatus Update
- Q2 net loss was $9.7M, $14.5M was raised, and $31.1M cash remains as clinical trials advance.INMBQ2 2024